Investments – Talk Bio

RTW-backed startup Yarrow Bioscience signs autoimmune antibody deal with China’s GenSci

3 days ago talkbio0Tagged anti-TSHR antibody, Antibodies, Autoimmune, Changchun GeneScience Pharmaceutical, China, GenSci, GS-098, Investments, RTW, strategic partnership, Thyroid associated opthalmopathies, Yarrow Bioscience, YB-101

RTW Investments; Yarrow Bioscience; GenSci; Changchun GeneScience Pharmaceutical; autoimmune; antibody; GS-098; YB-101; anti-TSHR antibody; thyroid eye disease; China; ex-China rights; strategic partnership; licensing deal

Health tech investors are getting creative with exits in 2025

1 week ago talkbio0Tagged 2025, AI healthtech IPOs, Exit, healthtech, Investments, M&A consolidation, Private Equity, provider operations, roll-ups, secondary markets, trends qualifier, Vital capacity

healthtech exits 2025; creative exit strategies; M&A consolidation; secondary markets; private equity roll-ups; AI healthtech IPOs; provider operations investment; VC healthtech trends

Pluri Appoints Alejandro Weinstein as Chairman of the Board to Lead Strategic Shift and Unlock Value, Backed by Additional Investment

1 week ago talkbio0Tagged Alejandro Weinstein, Biotechnology, Boards (medical device), commercialization, Corporate, governance, Health care facility, Investments, M&A transactions, ownership increase, Pluri, strategic shift, Surgical construction, Zami Aberman

Pluri; Alejandro Weinstein; Chairman of the Board; strategic shift; additional investment; ownership increase; Zami Aberman; Vice Chairman; biotechnology; healthcare; M&A transactions; value creation; commercialization; corporate governance

Biotech interest shifting from obesity ‘halo’ to other areas like oncology and blood cancers

2 weeks ago talkbio0Tagged Autoimmune, biotech pivot, Halo brace, Investments, leukemia, Neoplasms, Novartis, Obesity, sector rotation

obesity drugs; biotech pivot; investment trends; Novartis; leukemia; obesity halo; sector rotation; autoimmune; oncology

Tessera Therapeutics Strikes $150M Partnership with Regeneron for Gene Writing Therapy

3 weeks ago talkbio0Tagged alpha 1-Antitrypsin Deficiency, gene therapy, Gene Writing, Investments, Partnership, Regeneron, Tessera, TSRA-196

Tessera Therapeutics; Regeneron; gene writing; TSRA-196; AATD; alpha-1 antitrypsin deficiency; gene therapy; partnership; investment

Rakovina Therapeutics Announces Q3 2025 Financial Results and Corporate Update

3 weeks ago talkbio0Tagged AI-powered, ATR Inhibitor, Clinical Nurse Specialists, Conferences, corporate milestones, development expenses, Ditiocarb, Drug Discovery, Eligibility Determination, financial results, Investments, NanoPalm joint-venture, net loss, Penetration, Q3, Rakovina, research

Rakovina Therapeutics; Q3 2025; financial results; net loss; research and development expenses; AI-powered drug discovery; ATR inhibitor; CNS penetration; corporate milestones; NanoPalm joint-venture; investment conference; DTC eligibility

Novartis Announces Plans to Lay Off 550 Workers at Swiss Factory

3 weeks ago talkbio0Tagged Investments, layoffs, Novartis, pharmaceutical manufacturing, restructuring, Schweizerhalle, Stein facility, Switzerland

Novartis; layoffs; Switzerland; Stein facility; pharmaceutical manufacturing; restructuring; Schweizerhalle investment

AstraZeneca Onshores Rare Disease Portfolio as Part of $50B US Investment Pledge

4 weeks ago talkbio0Tagged AstraZeneca, expansion, Infrequent, Investments, Maryland (geographic location), onshoring, pledge, portfolio, R&D, U.S., Virginia facility

AstraZeneca; rare disease portfolio; onshoring; US investment; biomanufacturing; $50 billion pledge; Virginia facility; Maryland investment; R&D expansion

Eli Lilly to Acquire Adverum Biotechnologies in Gene Therapy Deal; Captain T Cell Secures €20M Funding

1 month ago talkbio0Tagged Acquisition, Adverum Biotechnologies, biotech, Captain T Cell, contingent value rights, CVR, eli lilly, financing characteristics, gene therapy, Investments, Ixo-vec, Ophthalmology specialty

Eli Lilly; Adverum Biotechnologies; Acquisition; Gene therapy; Ixo-vec; Contingent Value Rights (CVR); Ophthalmology; Captain T Cell; Financing; Biotech investment

From Weight Loss to Hair Loss: The Search for the Next Blockbuster – Recent Developments and News (2024-2025)

1 month ago talkbio0Tagged Alopecia, Androgenetic Alopecia, baldness cure, blockbuster drugs, Glucagon-Like Peptide 1, Investments, minoxidil, pattern hair loss, Pelage Pharmaceuticals, PP405, Veradermics, Weight-Loss Agents

weight loss drugs; GLP-1; hair loss treatments; Pelage Pharmaceuticals; Veradermics; blockbuster drugs; pattern hair loss; baldness cure; minoxidil; PP405; androgenetic alopecia; biotech investment